Risperidone (depot) for schizophrenia

Cochrane Database of Systematic Reviews

Volumn 2016, Issue 4, 2016, Pages

  Sampson, Stephanie ^a   Hosalli, Prakash ^b   Furtado, Vivek A ^c   Davis, John M ^d  

^a UNIVERSITY OF NOTTINGHAM   (United Kingdom)

^b SEACROFT HOSPITAL   (United Kingdom)

^c UNIVERSITY OF WARWICK   (United Kingdom)

^d UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PLACEBO; RISPERIDONE; ARIPIPRAZOLE; BENZODIAZEPINE DERIVATIVE; DELAYED RELEASE FORMULATION; NEUROLEPTIC AGENT; OLANZAPINE; QUETIAPINE;

ADVERSE DRUG REACTION; BIOSIS; CINAHL; COST EFFECTIVENESS ANALYSIS; DRUG COST; EMBASE; HEALTH CARE UTILIZATION; HUMAN; MEDLINE; MENTAL HEALTH; OUTCOME ASSESSMENT; PATIENT SATISFACTION; PRIORITY JOURNAL; PSYCINFO; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SCHIZOPHRENIA; SYSTEMATIC REVIEW; DELAYED RELEASE FORMULATION; META ANALYSIS; ORAL DRUG ADMINISTRATION; PATIENT DROPOUT; STATISTICS AND NUMERICAL DATA; THERAPEUTIC USE;

ADMINISTRATION, ORAL; ANTIPSYCHOTIC AGENTS; ARIPIPRAZOLE; BENZODIAZEPINES; DELAYED-ACTION PREPARATIONS; HUMANS; PATIENT DROPOUTS; QUETIAPINE FUMARATE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISPERIDONE; SCHIZOPHRENIA;

EID: 84963690300     PISSN: None     EISSN: 1469493X     Source Type: Journal    
DOI: 10.1002/14651858.CD004161.pub2     Document Type: Review

References (132)

1. Bai YM, Chen TT, Wu B, Hung CH, Lin WK, Hu TM, et al. A comparative efficacy and safety study of long-acting risperidone injection and risperidone oral tablets among hospitalized patients: 12-week randomized, single-blind study. Pharmacopsychiatry 2006;39(4):135-41.
2. Chue P, Eerdekens M, Augustyns I, Lachaux B, Molcan P, Eriksson L, et al. Efficacy and safety of long-acting risperidone microspheres and risperidone oral tablets. Schizophrenia Research (Abstracts of the 11th Biennial Winter Workshop on Schizophrenia) 2002;3(Suppl 1):174.
3. Chue P, et al. Maintenance of efficacy when switching from oral risperdal to risperdal consta RIS-INT-61. Promotional slides on file from Janssen-Cliag UK Ltd 2002.
4. Covell NH, McEvoy JP, Schooler NR, Stroup TS, Jackson CT, Rojas IA, et al. Effectiveness of switching from long-acting injectable fluphenazine or haloperidol decanoate to long-acting injectable risperidone microspheres: an open-label, randomized control trial. Journal of Clinical Psychiatry 2012;73(5):669-75.
5. Fleischhacker WW, Gopal S, Lane R, Gassmann-Mayer, Lim P, Hough D, et al. A randomized trial of paliperidone palmitate and risperidone long acting injectable in schizophrenia. International Journal of Neuropsychopharmacology 2012;15:107-18.
6. Gaebel W, Bergmans P, De Arce R, Rouillon F, Cordes J, Eriksson L, et al. Relapse prevention in schizophrenia and schizoaffective disorder with risperidone long-acting injectable versus quetiapine:Randomized, long-term, open-label, clinical trial results (constatre). Proceedings of the 17th European Psychiatric Association, EPA Congress; 2009 Jan 24-28; Lisbon Portugal 2009;24:S1020.
7. Gaebel W, Schreiner A, Bergmans P, De Arce R, Rouillon F, Cordes J, et al. Relapse prevention in schizophrenia and schizoaffective disorder with risperidone long-acting injectable vs quetiapine: Results of a long-term, open-label, randomized clinical trial. Neuropsychopharmacology 2010;35(12):2367-77.
8. Medori R, Wapenaar R, de Arce R, Rouillon F, Gaebel W, Cordes J, et al. Relapse prevention and effectiveness in schizophrenia of risperidone long-acting injectable (rlai) versus quetiapine or aripiprazole. Proceedings of the 161st Annual Meeting of the American Psychiatric Association; 2008 May 3-8; Washington DC, USA. 2008.
9. Rouillon F, Eriksson L, Burba B, Raboch J, Kaprinis G, Schreiner A. Functional recovery in schizophrenia and schizoaffective disorder: Results from the risperidone long-acting injectable versus quetiapine relapse prevention trial (constatre). Proceedings of the 17th European Psychiatric Association, EPA Congress; 2009 Jan 24-28; Lisbon Portugal 2009;24:S1023.
10. Schreiner A, Rouillon F, Eriksson L, Burba B, Raboch J, Kaprinis G, et al. Functional improvement in schizophrenia and schizoaffective disorder: results from the risperidone long-acting injectable versus quetiapine relapse prevention trial (ConstaTRE). Biological Psychiatry 2009:382.
11. Schreiner A, de Arce R, Eding E, Marques-Teixeira J, Milanova V, Rancans E, et al. Descriptive analyses of the aripiprazole arm in the risperidone long-acting injectable versus quetiapine relapse prevention trial (ConstaTRE). Biological Psychiatry 2009:381.
12. Smeraldi E, Cavallaro R, Folnegovic Smalc V, Bidzan L, Ceylan E, Schreiner A, et al. Long-term remission in schizophrenia and schizoaffective disorder: Results from the risperidone long-acting injectable versus quetiapine relapse prevention trial (constatre). Proceedings of the 17th European Psychiatric Association, EPA Congress; 2009 Jan 24-28; Lisbon Portugal 2009;24:S1021.
13. Smeraldi E, Cavallaro R, Smalc VF, Bidzan L, Ceylan ME, Schreiner A, et al. Long-term remission in schizophrenia and schizoaffective disorder: results from the risperidone long-acting injectable versus quetiapine relapse prevention trial (ConstaTRE). Biological Psychiatry 2009:389.
14. de Arce Cordón R, Eding E, Marques-Teixeira J, Milanova V, Rancans E, Schreiner A. Descriptive analyses of the aripiprazole arm in the risperidone long-acting injectable versus quetiapine relapse prevention trial (ConstaTRE). European Archives of Psychiatry and Clinical Neuroscience March 2010;262:139-49.
15. Anonymous. Injectible, long-acting risperidone effective. Journal of Pharmacy Technology 2001;4:157.
16. Kane J, Eerdekens M, Keith S, Lesem M, Karcher K, Lindenmayer J-P. Efficacy and safety of a novel long-acting risperidone formulation. European Psychiatry (11th Association of European Psychiatrists Congress, 2002 4-8th May, Stockholm, Sweden) 2002;17(Suppl 1):S193.
17. Kane J, Eerdekens M, Keith S, Lesem M, Karcher K, Lindenmayer JP. Long-acting risperidone microspheres for treatment of patients with schizophrenia. European Neuropsychopharmacology (Abstracts of the 14th Congress of the European College of Neuropsychopharmacology; 2001 Oct 13-17; Istanbul, Turkey) 2001;11(3):291.
18. Kane J, Eerdekens M, Keith SJ, Lesem M, Karcher K, Lindenmayer JP. Efficacy and safety of risperdal consta, the long-acting injection risperidone formulation. International Journal of Neuropsychopharmacology (Abstracts of the 23rd Congress of the Collegium Internationale Neuro-Psychopharmacologicum; 2002 Jun 23-27; Montreal, Canada) 2002;5(Suppl 1):S188.
19. Kane JM, Eerdekens M, Keith SJ, Lesem M, Karcher K, Lindenmayer J-P. Efficacy and safety of a novel long-acting risperidone microspheres formulation. Schizophrenia Research (Abstracts of the 11th Biennial Winter Workshop on Schizophrenia) 2002;53(3 Suppl.1):174.
20. Kane JM, Eerdekens M, Keith SJ, Lesem M, Karcher K, Lindenmayer JP. Efficacy and safety of risperdal consta (TM), a long-acting injection risperidone formulation RIS-USA-121. Promotional slides on file from Janssen-Cliag UK Ltd 2002.
21. Kane JM, Eerdekens M, Keith SJ, Lesem M, Karcher K, Lindenmayer JP. Long-acting injectable risperidone: Efficacy and safety. European Neuropsychopharmacology: Journal of the European College of Neuropsychopharmacology (15th ECNP Congress; October 5-9, 2002, Barcelona-Spain 2002;12(Supplement 3):S325.
22. Kane JM, Eerdekens M, Lindenmayer JP, Keith SJ, Lesem M, Karcher K. Long-acting injectable risperidone: efficacy and safety of the first long-acting atypical antipsychotic. American Journal of Psychiatry 2003;160(6):1125-32.
23. Keks N, Ingham M, Khan A, Karcher K. Long-acting injectable risperidone v. olanzapine tablets for schizophrenia or schizoaffective disorder: Randomised, controlled, open-label study. British Journal of Psychiatry 2007;191:131-9.
24. Keks N, Khan A, Augustyns I, Rabinowitz J, Ingham M. Non-inferiority efficacy trial of risperidone long-acting injection (RLAI) vs. olanzapine tablets (OLA). Proceedings of the 13th Biennial Winter Workshop on Schizophrenia Research; 2006 Feb 4-10; Davos, Switzerland. 2006.
25. Li H, Rui Q, Ning X, Xu H, Gu N. A comparative study of paliperidone palmitate and risperidone long-acting injectable therapy in schizophrenia. Progress in Neuro-Psychopharmacology & Biological Psychiatry 2011;35:1002-8.
26. MacFadden W, Yi-Wen M, Haskins JT, Bossie CA, Alphs L. A prospective study comparing the long-term effectiveness of injectable risperidone long-acting therapy and oral aripiprazole in patients with schizophrenia. Psychiatry 2010;7(11):23-31.
27. Pandina G, Lane R, Gassmann-Mayer C, Hough D, Remmerie B, Simpson G. A randomised double blind study of flexible doses of paliperidone palmitate and risperidone long acting therapy in patients with schizophrenia. Proceedings of the 27th International College of Neuropsychopharmacology Congress; 2010 June 6-10; Hong Kong. 2010.
28. Pandina G, Lane R, Gopal S, Gassman-Mayer C, Hough D, Remmerie B, et al. A randomized double blind study of flexible doses of paliperidone palmitate and risperidone long acting therapy in patients with schizophrenia. Biological Psychiatry 2010;67(9):77-8.
29. Pandina G, Lane R, Gopal S, Gassmann-Mayer C, Hough D, Remmerie B, et al. A double-blind study of paliperidone palmitate and risperidone long-acting injectable in adults with schizophrenia. Progress in Neuro-Psychopharmacology & Biological Psychiatry 2011;35:218-26.
30. Quinn A, Camacho F, Mitchell D, Chue P, Malla A. Open-label randomized exploratory investigation of Risperdal* Consta* and oral antipsychotics treatment of early psychosis. Autumn Conference of the International Society for CNS Clinical Trials and Methodology, October 1-3. Marina Del Rey, California, 2012.
31. Barnett PG, Scott JY, Krystal JH, Rosenheck RA. Cost and cost-effectiveness in a randomized trial of long-acting risperidone for schizophrenia. Journal of Clinical Psychiatry 2012;73:696-702.
32. Rosenheck RA, Krystal JH, Lew R, Barnett PG, Fiore L, Valley D, et al. Long- acting risperidone and oral antipsychotics in unstable schizophrenia. New England Journal of Medicine March 3, 2011;364(9):842-51.
33. Agid O, Foussias G, Remington G. Long acting injectable antipsychotics in the treatment of schizophrenia: Their role in relapse prevention. Expert Opinion on Pharmacotherapy 2010;11(14):2301-17.
34. Bouchard RH, Merette C, Pourcher E, Demers MF, Villeneuve J, Roy Gagnon MH, et al. The Quebec Schizophrenia Study Group. Longitudinal comparative study of risperidone and conventional neuroleptics for treating patients with schizophrenia. Journal of Clinical Psychopharmacology 2000;20(3):295-304. [MEDLINE: 20289861]
35. Canas F, Moller HJ. Long acting atypical injectable antipsychotics in the treatment of schizophrenia: Saftey and tolerability review. Expert Opinion on Drug Saftey 2010;9(5):683-97.
36. DeMartinis N, Banerjee A, Kumar V, Boyer S, Schmidt C, Arroyo S. Results of a phase 2a proof-of-concept trial with a PDE10A inhibitor in the treatment of acute exacerbation of schizophrenia. Schizophrenia Research 2012;136:S262.
37. Chue P, Devos E, Duchesne I, Leal A, Mehnert A. Hospitalization rates in patients during long-term treatment with long-acting risperidone injection. Poster presented at the XXIII CINP Congress, Montreal, Canada. June 23- 27, 2002.
38. Eerdekens M, Fleischhacker WW, Xie Y, Gefvert O. Long-term safety of long-acting risperidone microspheres. Schizophrenia Research (Abstracts of the 11th Biennial Winter Workshop on Schizophrenia) 2002;3(Suppl 1):174.
39. Fleischhacker WW, Eerdekens M, Xie Y, Beauclair L, Sauret H, Chrzanowski W, et al. Long-term saftey and efficacy of risperdal consta(TM) a long-acting injection formulation of risperidone. ACNP, Hawaii, USA, December 2001 (Promotional slides on file from Janssen-Cliag UK Ltd) 2002.
40. Eerdekens M. Treatment delivery: a hope for the future. Nordic Journal of Psychiatry (Abstracts of The Scandinavian College of Neuro-Psychopharmacology Annual Conference; 2002 10-13 Apr Juan-Les-Pins, France) 2002;56(2):1.
41. Gallhofer B. Cognitive dysfunction in schizophrenia: comparison of treatment with a novel atypical antipsychotic agent versus conventional neuroleptic drugs. 8th Congress of the European College of Neuropsychopharmacology; 1995 Sep 30 - Oct 4; Venice, Italy. 1995.
42. Geffen Y, Keefe R, Rabinowitz J, Anand R, Davidson M. Bl-1020, a new -aminobutyric acid-enhanced antipsychotic: Results of 6-week, randomized, double-blind, controlled, efficacy and safety study. Journal of Clinical Psychiatry 2012;73(9):e1168-e74.
43. Gefvert O, Nyberg S, Persson P, Helklin L, Bjorner A. Pharmacokinetics, D2 receptor occupancy, and clinical effects of a long-acting injectable formulation of risperidone in patients with schizophrenia. Annual Meeting of the American Psychiatric Association; 2001 May 5-10; LA, USA. Marathon Multimedia, 2001.
44. Kogeorgos J, Kanellos P, Michalakeas A, Ioannidis J. Sulpiride and risperidone vs. "classical neuroleptics" in schizophrenia: a follow-up study. 8th Congress of the European College of Neuropsychopharmacology; 1995 Sep 30 - Oct 4; Venice, Italy. 1995.
45. Koola MM, Bustillo J, Lauriello J. Insight and its to baseline characteristics of schizophrenia patients randomized to long acting injectable risperidone or oral atypical antipsychotics: results from the proactive study. Proceedings of the 12th International Congress on Schizophrenia Research; 2009 Mar 28- Apr 1; San Diego, CA. Oxford Univ Press, 2009.
46. Lindenmayer J, Grochowski S, Hyman RB. Five factor model of schizophrenia - replication across samples. Schizophrenia Research 1995;14(3):229-34. [MEDLINE: 95283955]
47. Litman R, Smith M, Doherty J, Cross A, Raines S, Zukin S. AZD8529, a positive allosteric modulator at the MGGLUR2 receptor, does not improve symptoms in schizophrenia: A proof of principle study. European Neuropsychopharmacology 2014;24:S508-9.
48. Litman RE, Smith MA, Doherty J, Cross A, Raines S, Zukin S. AZD8529, a positive allosteric modulator at the mGLuR2 receptor, does not improve symptoms in schizophrenia: A proof of principle study. Schizophrenia Research 2014;153:S176.
49. Littrell KH. Patients switched from depot antipsychotics to oral risperidone or olanzapine: an open-label randomized trial. 152nd Annual Meeting of the American Psychiatric Association; 1999 May 15-20; Washington, USA. 1999. [MEDLINE: 95283955]
50. Lloyd K, Latif MA, Simpson S, Shrestha KL. Switching stable patients with schizophrenia from depot and oral antipsychotics to long acting injectable risperidone: Efficacy, quality of life and functional outcome. Human Psychopharmacology 2010;25(3):243-52.
51. MacFadden W, Bossie CA, Turkoz I, Haskins JT. Risperidone long acting therapy in stable patients with recently diagnosed schizophrenia. International Clinical Psychopharmacology 2010;25(2):75-82.
52. Macfadden W, Bossie C, Turkoz I, Diekamp B, Ibach B, Haskins JT. Effect of long acting injectable risperidone on clinical outcomes in recently diagnosed stable schizophrenia patients. Proceedings of the XXVI Collegium Internationale Neuro Psychopharmacologicum congress; 2008 Jul 13-17; Munich, Germany. 2008.
53. Macfadden W, Bossie C, Turkoz I, Dorson P, Haskins T. Effect of long acting injectable risperidone on clinical outcomes in stable schizophrenia patients with early illness. Proceedings of the 161st Annual Meeting of the American Psychiatric Association; 2008 May 3-8; Washington DC, USA 2008.
54. McClure MM, Koenigsberg HW, Reynolds D, Goodman M, New A, Trestman R, et al. The effects of risperidone on the cognitive performance of individuals with schizotypal personality disorder. Journal of Clinical Psychopharmacology 2009;29(4):396-8.
55. Pikalov A, Cucchiaro J, Ogasa M, Silva R, Hsu J, Xu J, et al. Effect of lurasidone on weight and metabolic parameters: A comprehensive database analysis. Schizophrenia Research 2012;136:S278.
56. Procyshyn RM, Barr AM, Flynn S, Schenk C, Ganesan S, Honer WG. Long acting injectable risperidone in treatment refractory patients: A 14 week open label pilot study. Schizophrenia Research 2010;123(2-3):273-5.
57. Ritchie C, Ames D, Chiu E, O'Connor D, Hall K, Hassett A. Schizophrenia cohort study of olanzapine v risperidone in the elderly (score): analysis of conversion period. International Psychogeriatrics (Abstracts of the 9th Congress of the International Psychogeriatric Association, "Challenges for the New Millennium: Professional, Cultural and Regional Diversity" 1999 Aug 15-20; Vancouver, Canada) 1999;11(Suppl 1):157-8.
58. Robinson G, Wheeler A, Byrd J, Visser S. Longer-term effects of switching from typical to atypical antipsychotics in patients with stable schizophrenia. Journal of the European College of Neuropsychopharmacology 2000;10(Suppl 3):S291.
59. Schmechtig A, Dourish C, Craig K, Dawson GR, Williams S, Deakin W, et al. Effects of risperidone, amisulpride and nicotine on eye movement control and their modulation by high schizotypy. Pharmacopsychiatry 2011;21:A99. [MEDLINE: BIOSIS:PREV201100575768]
60. Schmechtig A, Lees J, Dawson G, Dourish C, Craig K, Deakin B, et al. Effects of high schizotypy on control of eye movements: Modulation by antipsychotic drugs and nicotine. Proceedings of the 49th Annual Meeting of the Americam College of Neuropsychopharmacology; 2010 Dec 5-9; Miami, Florida. 2010.
61. Simpson GM, Mahmoud RA, Lasser RA, Kujawa M, Bossie CA, Turkoz I, et al. A 1-year double-blind study of 2 doses of long-acting risperidone in stable patients with schizophrenia or schizoaffective disorder. Journal of Clinical Psychiatry 2006;67:1194-203.
62. Vaughan K, McConaghy N, Wolf C, Myhr C, Black T. Community Treatment Orders: Relationship to clinical care, medication compliance, behavioural disturbance and readmission. Australian and New Zealand Journal of Psychiatry 2000;5:801-8.
63. Verma S, Subramaniam M, Abdin E, Sim K, Su A, Lee N, et al. Saftey and efficacy of long acting injectable risperidone in patients with schizophrenia spectrum disorders: A 6 month open label trial in Asian patients. Human Psychopharmacology 2010;25(3):230-5.
64. Weiden PJ, Goldfinger SM, Hindi A, Sunakawa A, Schooler NR. Acceptance of a recommendation of a long acting antipsychotic route in first episode schizophrenia: initial findings of a prospective randomized study. Proccedings of the 160th Annual Meeting of the American Psychiatric Association; 2007 May 19-24; San Diego, CA. 2007.
65. Weiden PJ, Schooler NR, Weedon JC, Elmouchtari A, Sunakawa, Goldfinger SM. A randomized controlled trial of long acting injectable risperidone vs continuation on oral atypical antipsychotics for first episode schizophrenia patients: initial adherence outcome. Journal of Clinical Psychiatry 2009;70(10):1397-406.
66. Weiden PJ, Schooler NR, Weedon JC, Elmouchtari A, Sunakawa-McMillan A. Maintenance treatment with long-acting injectable risperidone in first-episode schizophrenia: A randomized effectiveness study. Journal of Clinical Psychiatry 2012;73(9):1224-33.
67. Wiffen BDR, Rabinowitz J, Fleischhacker WW, David AS. Insight: Demographic differences and associations with one-year outcome in schizophrenia and schizoaffective disorder. Clinical Schizophrenia and Related Psychoses 2010;4(3):169-75.
68. Nasrallah H, Duchesne I, Mehnert A, Janagap C. Long-acting risperidone improves quality of life. Proceedings of the 12th World Congress of Psychiatry; 2002 Aug 24-29; Yokohama, Japan. 2002.
69. Nasrallah H, Duchesne I, Mehnert A, Janagap C. Long-acting risperidone injection improves quality of life. International Journal of Neuropsychopharmacology 2002;5(Suppl 1):S189.
70. Nasrallah H, Duchesne I, Mehnert A, Janagap C. Long-acting, injectable risperidone - the first long-acting, atypical antipsychotic - improves quality of life. European Neuropsychopharmacology 2002;12(Suppl 3):S282.
71. Nasrallah HA, Duchesne I, Mehnert A, Janagap C, Eerdekens M. Correction. Journal of Clinical Psychological Medicine 2004;65(8):1150.
72. Nasrallah HA, Duchesne I, Mehnert A, Janagap C, Eerdekens M. Health-related quality of life in patients with schizophrenia during treatment with long-acting, injectable risperidone. Journal of Clinical Psychiatry 2004;65(4):531-6. [MEDLINE: 15119916]
73. Segarra R, Ojeda N, Garcia J, Pena J, Bravo E, Eguiluz JI. Risperidone injectable long acting treatment vs other oral antipsychotics in first episode psychosis: One year longitudinal study. Schizophrenia Research. 2010; Vol. 117, issue 2-3:495.
74. Turner T. Risperidone depot v risperidone tablets: a non-inferiority efficacy trial in subjects with schizophrenia. National Research Register (http://www.update-software.com/National/) 2000.
75. Adams CE, Fenton MK, Quraishi S, David AS. Systematic meta-review of depot antipsychotic drugs for people with schizophrenia. British Journal of Psychiatry 2001;179:290-9.
76. Altman DG, Bland JM. Detecting skewness from summary information. BMJ 1996;313(7066):1200.
77. American Psychiatric Association. Diagnostic and sStatistical Manual of Mental Disorders: DSM-IV-TR. Washington, DC: American Psychiatric Association, 2000.
78. Barnes TR. A rating scale for drug-induced akathisia. British Journal of Psychiatry 1989;154:672-6.
79. Bland JM, Kerry SM. Statistics notes. Trials randomised in clusters. BMJ 1997;315(7108):600.
80. BMJ Group and Pharmaceautical Press. British National Formulary No. 63. Antipsychotic drugs. BNF 2012.
81. Boissel JP, Cucherat M, Li W, Chatellier G, Gueyffier F, Buyse M, et al. The problem of therapeutic efficacy indices. 3. Comparison of the indices and their use [Apercu sur la problematique des indices d'efficacite therapeutique, 3: comparaison des indices et utilisation. Groupe d'Etude des Indices D'efficacite]. Therapie 1999;54(4):405-11. [PUBMED: 10667106]
82. Cost-Effectiveness Analysis Registry (CEA). https://research.tufts-nemc.org/cear4/ accessed 11/09/13.
83. Chouinard G, Ross-Chouinard A, Annable L. Extrapyramidal symptom rating scale. Canadian Journal of Neurological Science 1980;7:233.
84. Clarke M, Oxman AD. Cochrane Collaboration Handbook. Cochrane Database of Systematic Reviews. Oxford: Update Software, 2002, issue 1.
85. Csernansky JG, Mahmood R, Brenner R, Risperidone-USA-79 Study Group. A comparison of risperidone and haloperidol for the prevention of relapse in patients with schizophrenia. New England Journal of Medicine 2002;346:16-22.
86. Davies LM, Lewis S, Jones PB, Barnes TR, Gaughran F, Hayhurst K, et al. Cost-effectiveness of first- v. second-generation antipsychotic drugs: results from a randomised controlled trial in schizophrenia responding poorly to previous therapy. British Journal of Psychiatry 2007;191:14-22.
87. Davis JM, Casper R. Antipsychotic drugs: clinical pharmacology and therapeutic use. Drugs 1977;14(4):260-82.
88. Davis JM, Andriukaitis S. The natural course of schizophrenia and effective maintenance drug treatment. Journal of Clinical Psychopharmacology 1986;6(1 Suppl):2S-10S.
89. Deeks J. Issues in the selection for meta-analyses of binary data. Proceedings of the 8th International Cochrane Colloquium; 2000 Oct 25-28; Cape Town. Cape Town: The Cochrane Collaboration, 2000.
90. Divine GW, Brown JT, Frazier LM. The unit of analysis error in studies about physicians' patient care behavior. Journal of General Internal Medicine 1992;7(6):623-9.
91. Donner A, Klar N. Issues in the meta-analysis of cluster randomized trials. Statistics in Medicine 2002;21:2971-80.
92. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997;315(7109):629-34.
93. Elbourne D, Altman DG, Higgins JPT, Curtina F, Worthingtond HV, Vaile A. Meta-analyses involving cross-over trials: methodological issues. International Journal of Epidemiology 2002;31(1):140-9.
94. Fenton WS, Blyler CR, Heinssen RK. Determinants of medication compliance in schizophrenia: empirical and clinical findings. Schizophrenia Bulletin 1997;23(4):637-51. [MEDLINE: 9366000]
95. Furukawa TA, Barbui C, Cipriani A, Brambilla P, Watanabe N. Imputing missing standard deviations in meta-analyses can provide accurate results. Journal of Clinical Epidemiology 2006;59(7):7-10.
96. Geddes J, Freemantle N, Harrison P, Bebbington P. Atypical antipsychotics in the treatment of schizophrenia: systematic overview and meta-regression analysis. BMJ 2000;321(7273):1371-6.
97. Gulliford MC, Ukoumunne OC, Chinn S. Components of variance and intraclass correlations for the design of community-based surveys and intervention studies: data from the Health Survey for England 1994. American Journal of Epidemiology 1999;149(9):876-83.
98. Guy W. Early clinical drug evaluation (ECDEU) assessment manual for psychopharmacology. ECDEU Assessment Manual for Psychopharmacology. Washington, DC: National Institute of Mental Health, 1976:217-22.
99. Health Economic Evaluation Database (HEED). Online ISBN: 9780470510933. [DOI: 10.1002/9780470510933]
100. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 2003;327:557-60.
101. Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.2 [updated September 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
102. Hunter R, Kennedy E, Song F, Gadon L, Irving CB. Risperidone versus typical antipsychotic medication for schizophrenia. Cochrane Database of Systematic Reviews 2003, Issue 2. [DOI: 10.1002/14651858.CD000440]
103. Janssen PA, Niemegeers CJ, Awouters F, Schellekens KH, Megens AA, Meert TF. Pharmacology of risperidone (R 64 766), a new antipsychotic with serotonin-S2 and dopamine-D2 antagonistic properties. Journal of Pharmacology and Experimental Therapeutics 1988;244(2):685-93.
104. Jayaram MB, Hosalli P, Stroup TS. Risperidone versus olanzapine for schizophrenia. Cochrane Database of Systematic Reviews 2006, Issue 2. [DOI: 10.1002/14651858.CD005237.pub2]
105. Kay SR, Opler LA, Fiszbein A. Positive and Negative Syndrome Scale (PANSS) Manual. North Tonawanda, NY: Multi-Health Systems, 1986.
106. Kay SR, Fiszbein A, Opler LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophrenia Bulletin 1987;13:261-76.
107. Kirkpatrick B, Buchanan RW, McKenny PD, Alphs LD, Carpenter WT. The schedule for the deficit syndrome: An instrument for research in schizophrenia. Psychiatry Research 1989;30(2):119-23.
108. Leucht S, Pitschel-Walz G, Abraham D, Kissling W. Efficacy and extrapyramidal side-effects of the new antipsychotics olanzapine, quetiapine, risperidone, and sertindole compared to conventional antipsychotics and placebo. A meta-analysis of randomized controlled trials. Schizophrenia Research 1999;35(1):51-68.
109. Leucht S, Kane JM, Kissling W, Hamann J, Etschel E, Engel RR. What does the PANSS mean?. Schizophrenia Research 2005;79(2-3):231-8. [PUBMED: 15982856]
110. Leucht S, Kane JM, Kissling W, Hamann J, Etschel E, Engel R. Clinical implications of brief psychiatric rating scale scores. British Journal of Psychiatry 2005;187:366-71. [PUBMED: 16199797]
111. Leucht S, Engel RR, Bauml J, Davis JM. Is the superior efficacy of new generation antipsychotics an artifact of LOCF?. Schizophrenia Bulletin 2007;33(1):183-91. [PUBMED: 16905632]
112. Li C, Xia J, Wang J. Risperidone dose for schizophrenia. Cochrane Database of Systematic Reviews 2009, Issue 4. [DOI: 10.1002/14651858.CD007474.pub2]
113. Lingjaerd O, Ahlfors UG, Bech P, Dencker SJ, Elgen K. The UKU side effect rating scale: A new comprehensive rating scale for psychotropic drugs and a cross-sectional study of side effects in neuroleptic-treated patients. Acta Psychiatrica Scandinavica 1987;76(s334):1-100.
114. Mangalore R, Knapp M. Cost of schizophrenia in England. Journal of Mental Health Policy and Economics 2007;10(1):23-41.
115. Marder SR, Meibach RC. Risperidone in the treatment of schizophrenia. American Journal of Psychiatry 1994;151(6):825-35.
116. Marshall M, Lockwood A, Bradley C, Adams C, Joy C, Fenton M. Unpublished rating scales: a major source of bias in randomised controlled trials of treatments for schizophrenia. British Journal of Psychiatry 2000;176:249-52.
117. McGahuey CA, Gelenberg AJ, Laukes CA, Moreno FA, Delgado PL, McKnight KM, et al. The Arizona Sexual Experience Scale (ASEX): reliability and validity. Journal of Sex and Marital Therapy 2000;26(1):25-40.
118. McGrath J, Saha S, Chant D, Welham J. Schizophrenia: a concise overview of incidence, prevalence, and mortality. Epidemiologic Reviews 2008;30(1):67-76.
119. Moher D, Schulz KF, Altman D, CONSORT Group. The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomized trials. 2001 JAMA;285(15):1987-91.
120. Munetz MR, Benjamin S. How to examine patients using the Abnormal Involuntary Movement Scale. Hospital Community Psychiatry 1988;39(11):1172-7.
121. Nafees B, van Hanswijck de Jonge P, Stull D, Pascoe K, Price M, Clarke A, et al. Reliability and validity of the Personal and Social Performance scale in patients with schizophrenia. Schizophrenia Research 2012;140(1-3):71-6.
122. Overall JE, Gorham DR. The brief psychiatric rating scale. Psychological Reports 1962;10:799-812.
123. Ramstack JM, Grandolfi GP, Mannaert E, D'Hoore P, Lasser RA. Risperdal CONSTA™: Prolonged-release injectable delivery of risperidone using Medisorb® Microsphere Technology. Schizophrenia 2003;60:314.
124. Sarfati Y, Olivier V, Bouhassira M. New antipsychotics in the treatment of schizophrenia. A European survey. Encephale 1999;25(6):658-66.
125. Schünemann HJ, Oxman AD, Vist GE, Higgins JPT, Deeks JJ, Glasziou P, et al. Chapter 12: Interpreting results and drawing conclusions. In: Higgins JPT, Green S editor(s). Cochrane Handbook for Systematic Reviews of Interventions. The Cochrane Collaboration, 2008:359-83.
126. Small JG, Hirsch SR, Arvanitis LA, Miller BG, Link CG, Seroquel Study Group. Quetiapine in patients with schizophrenia. A high- and low-dose double- blind comparison with placebo. Archives of General Psychiatry 1997;54(6):549-57.
127. Tollefson GD, Beasley CM Jr, Tamura RN, Tran PV, Potvin JH. Blind, controlled, long-term study of the comparative incidence of treatment-emergent tardive dyskinesia with olanzapine or haloperidol. American Journal of Psychiatry 1997;154(9):1248-54.
128. Ukoumunne OC, Gulliford MC, Chinn S, Sterne JAC, Burney PGJ. Methods for evaluating area-wide and organisation-based intervention in health and health care: a systematic review. Health Technology Assessment 1999;3(5):1-75.
129. Ware JE Jr, Sherbourne CD. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Medical Care 1992;30(6):473-83.
130. Xia J, Adams CE, Bhagat N, Bhagat V, Bhoopathi P, El-Sayeh H, et al. Loss to outcomes stakeholder survey: the LOSS study. Psychiatric Bulletin 2009;33(7):254-7.
131. Young JL, Zonana HV, Shepler L. Medication noncompliance in schizophrenia: codification and update. Bulletin of the American Academy of Psychiatry and the Law 1986;14(2):105-22.
132. Hosalli P, Davis JM. Depot risperidone for schizophrenia. Cochrane Database of Systematic Reviews 2003, Issue 4. [DOI: 10.1002/14651858.CD004161; PUBMED: 14584007]